Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
ITCIIntra-Cellular Therapies(ITCI) Zacks Investment Research·2024-05-07 21:41

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of 0.16pershareversustheZacksConsensusEstimateofalossof0.16 per share versus the Zacks Consensus Estimate of a loss of 0.31. This compares to loss of 0.46pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof48.390.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of 0.44 per share when it actually produced a loss of $0.30, delivering a surprise of 31.82%. Over the last four quart ...